Research Article

The evaluation of serum Pancreatic-derived factor and Malondialdehyde levels in patients with polycystic ovary syndrome

Volume: 13 Number: 3 September 18, 2020
TR EN

The evaluation of serum Pancreatic-derived factor and Malondialdehyde levels in patients with polycystic ovary syndrome

Abstract

Purpose: Alterations in β-cell function may play crucial roles in the pathogenesis of polycystic ovary syndrome (PCOS). Pancreatic-derived factor (PANDER) is a cytokine-like protein, inducing of pancreatic β-cell apoptosis under pathological conditions. This investigation was planned to determine serum PANDER levels and establish whether serum PANDER levels are related with oxidative stress, and insulin resistance in PCOS. Materials and Methods: Twenty-seven patients with PCOS and 24 healthy control women were evaluated in this controlled clinical study. Serum lipid sub-fractions, fasting glucose, insulin, gonadotropins, androgens, malondialdehyde (MDA) and PANDER levels were measured. Homeostasis model assessment (HOMA-IR) were used to estimate insulin resistance. Results: Subjects in study and control groups were similar with respect to waist measurements, gonadotropins, lipid sub-fractions, MDA and PANDER levels, the women with PCOS had considerably higher FAI and HOMA-IR than healthy women. Serum PANDER levels were not correlated with any studied parameters. Conclusion: These outcomes showed that PANDER level is not related with insulin resistance, ovarian hyperandrogenism and oxidative stress in PCOS.

Keywords

References

  1. 1 Ehrmann DA. Medical progress: polycystic ovary syndrome. N Engl J Med 2004: 352: 1223–1236
  2. 2 Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006; 113(10): 1210-1217.
  3. 3 Artimani T, Karimi J, Mehdizadeh M, et al. Evaluation of pro-oxidant-antioxidant balance (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2018; 34(2): 148-152.
  4. 4 Mohammadi S, Kayedpoor P, Karimzadeh-Bardei L, Nabiuni M. The Effect of Curcumin on TNF-α, IL-6 and CRP Expression in a Model of Polycystic Ovary Syndrome as an Inflammation State. J Reprod Infertil. 2017; 18(4): 352-360.
  5. 5 Amer SAK. Polycystic ovarian syndrome: diagnosis and management of related infertility. Obstet Gynaecol Reprod Med. 2009; 19(10): 263-270.
  6. 6 González F. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012; 77: 300-305.
  7. 7 Zhu Y, Xu GX, Patel A, et al. Cloning, expression and initial characterization of a novel cytokine like gene family. Genomics 2002; 80:144–150.
  8. 8 Cao X, Gao Z, Robert CE, et al. Pancreatic-derived factor (FAM3B), a novel islet cytokine, induces apoptosis of insulin-secreting beta-cells. Diabetes. 2003; 52(9): 2296-2303.

Details

Primary Language

English

Subjects

Obstetrics and Gynaecology

Journal Section

Research Article

Publication Date

September 18, 2020

Submission Date

March 6, 2020

Acceptance Date

July 3, 2020

Published in Issue

Year 2020 Volume: 13 Number: 3

APA
Çabuş, Ü., Kaleli, B., Fenkci, İ., Kaleli, İ., & Demir, S. (2020). The evaluation of serum Pancreatic-derived factor and Malondialdehyde levels in patients with polycystic ovary syndrome. Pamukkale Medical Journal, 13(3), 715-721. https://doi.org/10.31362/patd.699953
AMA
1.Çabuş Ü, Kaleli B, Fenkci İ, Kaleli İ, Demir S. The evaluation of serum Pancreatic-derived factor and Malondialdehyde levels in patients with polycystic ovary syndrome. Pam Med J. 2020;13(3):715-721. doi:10.31362/patd.699953
Chicago
Çabuş, Ümit, Babür Kaleli, İ.veysel Fenkci, İlknur Kaleli, and Süleyman Demir. 2020. “The Evaluation of Serum Pancreatic-Derived Factor and Malondialdehyde Levels in Patients With Polycystic Ovary Syndrome”. Pamukkale Medical Journal 13 (3): 715-21. https://doi.org/10.31362/patd.699953.
EndNote
Çabuş Ü, Kaleli B, Fenkci İ, Kaleli İ, Demir S (September 1, 2020) The evaluation of serum Pancreatic-derived factor and Malondialdehyde levels in patients with polycystic ovary syndrome. Pamukkale Medical Journal 13 3 715–721.
IEEE
[1]Ü. Çabuş, B. Kaleli, İ. Fenkci, İ. Kaleli, and S. Demir, “The evaluation of serum Pancreatic-derived factor and Malondialdehyde levels in patients with polycystic ovary syndrome”, Pam Med J, vol. 13, no. 3, pp. 715–721, Sept. 2020, doi: 10.31362/patd.699953.
ISNAD
Çabuş, Ümit - Kaleli, Babür - Fenkci, İ.veysel - Kaleli, İlknur - Demir, Süleyman. “The Evaluation of Serum Pancreatic-Derived Factor and Malondialdehyde Levels in Patients With Polycystic Ovary Syndrome”. Pamukkale Medical Journal 13/3 (September 1, 2020): 715-721. https://doi.org/10.31362/patd.699953.
JAMA
1.Çabuş Ü, Kaleli B, Fenkci İ, Kaleli İ, Demir S. The evaluation of serum Pancreatic-derived factor and Malondialdehyde levels in patients with polycystic ovary syndrome. Pam Med J. 2020;13:715–721.
MLA
Çabuş, Ümit, et al. “The Evaluation of Serum Pancreatic-Derived Factor and Malondialdehyde Levels in Patients With Polycystic Ovary Syndrome”. Pamukkale Medical Journal, vol. 13, no. 3, Sept. 2020, pp. 715-21, doi:10.31362/patd.699953.
Vancouver
1.Ümit Çabuş, Babür Kaleli, İ.veysel Fenkci, İlknur Kaleli, Süleyman Demir. The evaluation of serum Pancreatic-derived factor and Malondialdehyde levels in patients with polycystic ovary syndrome. Pam Med J. 2020 Sep. 1;13(3):715-21. doi:10.31362/patd.699953

Creative Commons Lisansı
Pamukkale Medical Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License